1. Introduction {#s0005}
===============

1.1. Viral commandment: stay unseen, do not let your dsRNA be detected {#s0150}
----------------------------------------------------------------------

The intrinsic innate immune system is the primary line of defense against virus invasion, which detects the presence of a virus in an infected cell through a set of proteins named *pathogen recognition receptors* (PRRs). PRRs recognize viral components, both proteins and nucleic acids, as signatures of "non-self" that are the sign of an infection in place and are named *pathogen-associated molecular patterns* (PAMPs) ([@b0685]). Upon PAMPs recognition, PRRs initiate a signaling cascade which culminates with the induction of type I alpha/beta interferons (IFN-α/β). These cytokines act in both an autocrine and paracrine manner to promote viral clearance or induce apoptosis in infected cells, to establish an antiviral state in non-infected cells and to modulate the priming of optimal antigen-specific T cell and antibody adaptive response ([@b1065]).

Viral PAMPs mainly consist of nucleic acids that may originate from the uncoating process of newly-infecting virions, the transcription of viral genes and the replication of genomic intermediates. Among these, double-stranded RNA (dsRNA) moieties, especially those with the atypically-featured 5′-triphosphate (5′-ppp) termini, have no homologues in the cytoplasm and therefore represent the most efficient triggers for PRRs activation ([@b0445]). Given the central dsRNA role in stimulating IFN-α/β induction, a subset of PRRs is specifically dedicated to its detection and, depending on their cell compartments localization, can be ascribed to two families. dsRNA recognition in endosomes, lysosomes and even at the extracellular surface is accomplished by the Toll-like receptor 3 (TLR-3), a member of the TLR family ([@b0055]), while dsRNA recognition in the cytosolic environment is carried out by RNA helicases belonging to the retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) family ([@b1320]), named after the first characterized member, RIG-I ([@b1360]).

Because RNA viruses tend to accumulate nucleic acid intermediates and byproducts in the host cytoplasm during their replication cycle, preventing recognition by host PRRs of such PAMPs is of crucial importance. Therefore, most, if not all, RNA viruses encode proteins that display IFN-antagonism properties aimed to circumvent the host innate immune system. Among those proteins, most have been revealed as involved in targeting the RLR pathway at several levels ([@b1260]). The impact of this counteraction becomes particularly evident for those RNA viruses that cause severe diseases in humans, since in several cases the fatal outcome has been related to their ability to subvert the type I IFN-mediated innate immune response ([@b0135]). It is therefore not surprising that, among the different viral proteins identified as inhibitors of IFN-α/β production and signaling, most are also molecular determinants of virulence and pathogenesis ([@b0125], [@b1260]).

This review focuses on the strategies adopted by several highly pathogenic RNA viruses to suppress type I IFN induction at the level of dsRNA detection by RLRs. Even relying on the extremely variegated arsenal found in the biodiversity of viral proteins, these strategies can be categorized into three main lines of action:(i)hiding the dsRNA to make it inaccessible to RLRs,(ii)masking the dsRNA PAMP signatures to avoid their recognition by RLRs,(iii)hitting the components of the RLRs pathway to destroy their functionalities ([Fig. 1](#f0005){ref-type="fig"} ).Fig. 1Schematic representation of RLR-mediated type I IFN induction and viral strategies aimed at its suppression. Recognition of viral dsRNA by RLRs leads to the production of type I IFN-α/β, triggering an innate immune antiviral response. Viruses prevent it by processing dsRNA (*Mask*), sequestering dsRNA (*Hide*) or physically interacting with the host proteins involved in the RLRs pathway (*Hit*).

As representatives of the three different strategies, some prominent human RNA viruses have been here chosen on the basis of their lethality, their status of emerging or re-emerging pathogens and the substantial lack of therapeutics to counter the deadly diseases they cause. In light of recent functional, biochemical and structural findings, the mechanisms of action by which these virally-encoded IFN-antagonists cause a failure in RLR activation and signaling are discussed.

2. The origin of dsRNA as a viral PAMP {#s0010}
======================================

The existence of dsRNA as a byproduct of replication and transcription steps in the replication cycle of all viruses was proposed about half a century ago ([@b0365], [@b0865]) and it was hypothesized that it could serve as a potent stimulus for IFN-α/β induction ([@b0370]). Accordingly, it was demonstrated that the addition of dsRNA, of either viral ([@b0915], [@b1230]) or synthetic origin ([@b0375]), to the culture medium of several cell lines, as well as its intracellular delivery, resulted in a robust type I IFN response ([@b0815]). Thereafter, several studies aimed to dissect the cellular IFN-based antiviral response by using polyinosinic:polycytidylic acid (polyI:C) to mimic the dsRNA intermediates that are present during viral infections. After more than two decades, such efforts led to the identification of TLR3 as the receptor responsive to dsRNA internalized by endocytosis ([@b0015]) and, later, to the discovery of RLRs as the class of molecules that detects dsRNA in the cytoplasm ([@b0035], [@b1360], [@b1355]).

Indeed, how and when base-paired RNA sequences were generated and/or were freely exposed during infection by different viruses has represented the main question of several studies. On the one hand, the use of polyI:C as viral mimetic, while demonstrating that the double-helical nature of RNA is itself a potent IFN inducer ([@b0525]), somehow depicted an artificial recognition process by RLRs. On the other hand, while viral dsRNAs of genomic length were able to activate RLRs pathway to induce IFN-α/β ([@b0310], [@b0605]), immunofluorescence analysis with dsRNA-specific monoclonal antibody showed detectable amounts of dsRNA only in cells infected by some positive-stranded (+)-RNA viruses, whereas no dsRNA was detected in cells infected by negative-stranded (−)-RNA viruses ([@b1300]). Currently, apart from dsRNA viruses for which the dsRNA PAMP is the viral genome itself, it is generally assumed that other viruses produce this PAMP as a replicative byproduct. In DNA viruses, for example, dsRNA may be generated through the self-annealing of convergent bidirectional transcription products ([@b1300]). (+)-RNA viruses, whose single-stranded genomes directly serve for the translation of viral proteins, generate (−)-ssRNA antigenome templates and newly-synthesized (+)-ssRNA genomes during their replication, and both these products are susceptible of base-pairing into dsRNA with their complementary template strand ([@b0010]). (−)-RNA viruses transcribe monocistronic mRNAs from every gene and during the replication step synthesize viral genomes and antigenomes from a template that is tightly encapsidated by nucleoproteins. This encapsidation occurs concomitantly to RNA synthesis, since it is strictly required by the viral RNA-dependent RNA polymerase (RdRp) complex for its attachment and progression along the template ([@b0870]). As a result, RNA encapsidation also prevents double-strand formation, since no genomic or antigenomic intermediates are normally found naked in the cytoplasm and they therefore cannot anneal to each other to produce dsRNA moieties ([@b0445]).

Notably, prevention of dsRNA formation may also involve the recruitment of host factors, as the downregulation of the cellular helicase UAP56, which was found to unwind self-paired transcripts from influenza A virus (IAV), resulted in cytosolic accumulation of viral dsRNA ([@b1325]). However, viral replication and transcription are both processes susceptible to errors, which may lead to occasional production of defective transcripts and abortive 5′-genome and antigenome ends that, annealing one to each other or self-pairing into panhandle-like secondary structures, become ideal IFN-inducing viral PAMP candidates ([@b0445]). In line with this, defective interfering (DI) RNAs generated through genome copyback during Sendai virus (SeV) infection, as well as subgenomic DI particles from IAV were found to potently activate the IFN response and act as RLR ligands ([@b1165], [@b0080]).

Proteins having dsRNA-binding motifs recognize this nucleic acid in a sequence-independent manner and on the basis of its A-type helical grooves and negative charge ([@b0175], [@b1220]). Moreover, the presence of an RNA double helix is essential for RLRs to induce a type I IFN-based response ([@b1110]), as ssRNA molecules which did not undergo self-pairing and double-stranded secondary structures were unable to bind and activate RIG-I ([@b1115], [@b1120]). However, the fact that some endogenous short dsRNAs of annealed antisense transcripts and microRNA precursors with secondary-stem loops -- that are occasionally present at low levels in mammalian cells -- do not elicit any IFN response, demonstrated that RNA double-strandness alone may be not sufficient for proper RLRs stimulation ([@b0705], [@b0820], [@b1315]).

In fact, other features are also important, as the ability of viral dsRNA species to trigger a type I IFN-induced antiviral response is dictated by their atypical length, abundance, cytoplasmic localization ([@b0310], [@b0605]) and, (only for RIG-I), by the presence of a 5′-ppp at their termini ([@b0540], [@b0995], [@b1115], [@b1120]). 5′-ppp moieties originate from the first-added nucleotide during the primer-independent initiation of viral RNA synthesis, within both transcription and replication processes ([@b0240]). At the end of transcription, covalent attachment of a cap structure assures the complete removal of 5′-ppp ([@b0295]), whereas the triphosphates at 5′-genome termini are either processed or enwrapped by viral nucleoproteins into homo-polymeric nucleocapsids ([@b0240]). However, 5′-ppp groups may be inadvertently exposed to the cytosolic environment in byproducts such as leader RNAs, as well as defective replicative intermediates that remain uncapped ([@b0445]). In addition to viral genome replication and transcription, the uncoating process to which viral nucleocapsids are subjected immediately after infection represents another critical moment for the recognition of 5′-ppp and panhandle structures. In line with this, a recent study showed that RIG-I was able to physically interact with, and to be activated by, nucleocapsids from several negative-stranded (−)-RNA viruses, independently from viral RNA synthesis ([@b1305]).

Thus, even though it remains to be shown if such interaction involves intact nucleocapsids, or rather implies the exposure of dsRNA tracts accessible within them, these findings establish the cytosolic release of incoming virions as the possible earliest event for RIG-I detection of viral dsRNA ([@b1305]). In summary, byproducts of viral replication and transcription ([@b1070]) or DI RNAs ([@b0080], [@b1165]), as wells as unmodified 5′-ppp ends and dsRNA panhandle structures that come from newly-infecting virions ([@b1305]) are all theoretically prone to provide double-stranded structures, originated through self-pairing or annealing with complementary sequences. Therefore, it is conceivable that all these together may represent the overall source of dsRNA ligands for RLRs activation.

3. RLRs: structure and pathway {#s0015}
==============================

The RLRs are a set of cytosolic sensors for dsRNA belonging to the superfamily 2 (SF2) clade of RNA helicases ([@b0345]). In addition to RIG-I ([@b1360]), this group includes also the melanoma differentiation associated factor-5 (MDA5) and the laboratory of genetics and physiology-2 (LGP2) proteins ([@b0035], [@b1355]).

RLRs share a similar structural organization ([Fig. 2](#f0010){ref-type="fig"} ), consisting of an RNA-binding C-terminal domain (CTD) ([@b0270], [@b1200], [@b1195]) and a central DExD/H-box helicase domain comprising two RecA-like helicase domains, namely Hel1 and Hel2, separated by the insert domain Hel2i ([@b0800]). In RIG-I and MDA5, but not in LGP2, the helicase domain is preceded by two tandemly-repeated N-terminal caspase activation and recruitment domains (CARDs) ([@b1355]). Unlike other members of the SF2 helicases, which bind one strand of the nucleic acid to unwind its double helix ([@b0345]), RLRs have double-strand specificity and do not seem to display unwinding activity. Indeed, a weak unwinding was initially described for a RIG-I deletion mutant ([@b0820]) as well as for the full length protein in the presence of dsRNA substrates with overhangs at the 3′ strand longer than 5 nts ([@b1200]). However, lack of RIG-I helicase activity was reported by subsequent studies ([@b0900], [@b0585]). Instead, RLRs bind to both dsRNA strands and translocate onto it in an ATP hydrolysis-dependent manner ([@b0050], [@b0900]).Fig. 2Structural organization of RLRs. RIG-I, MDA5 and LGP2 share an overall domain organization that consists of two tandemly-repeated N-terminal CARDs (orange boxes, absent in LGP2) followed by an Hel domain (green box in RIG-I and MDA5, blue box in LGP2) and a C-terminal RNA binding CTD (violet, azure and cyan box in RIG-I, MDA5 and LGP2 respectively).

According to the current model (schematically depicted in [Fig. 3](#f0015){ref-type="fig"} ), physiologically inactive RIG-I is found in an auto-inhibited state, in which the two CARDs are kept engaged in intramolecular interactions with the Hel2i domain by a repressor pincer motif located between the CTD and the helicase domains ([@b0665]). Upon dsRNA binding to the CTD ([@b0245]), the pincer motif is relieved from CARDs that are then displaced from the Hel2i allowing its binding to dsRNA ([@b0800]). Subsequent to dsRNA enwrapping to Hel domains, RIG-I dimerization and activation of its ATPase activity take place ([@b0270]). ATP hydrolysis propels the translocation of the RIG-I dimer along dsRNA ([@b0900]) and an overall conformational change releases N-terminal CARDs for signaling ([@b0580]). Freely exposed RIG-I CARDs then interact with unanchored Lys-63-linked poly-ubiquitin (poly-Ub) chains ([@b1385]). Next, RIG-I homo-oligomerization and ATP-ase-driven translocation along dsRNA take place ([@b0975]), leading to additional conformational changes that provide the signaling platform for interaction with the CARDs of the IFN-β promoter stimulator 1 (IPS-1) ([@b0615]). This is a mitochondrion-associated protein, now called mitochondrial antiviral signaling protein (MAVS) ([@b1130]), formerly also known as IFN-β inducing CARD adaptor (Cardif) ([@b0855]) or virus-induced signaling adaptor (VISA) ([@b1340]).Fig. 3Activation of the type I IFN antiviral response triggered by the RLRs pathway upon dsRNA detection. Viral short 5′-ppp dsRNA and long dsRNA are preferentially recognized by the CTD of RIG-I (violet) and of MDA5 (azure) respectively, with LGP2 modulating the activity of RIG-I helicase. Upon dsRNA binding to their Hel domain (green), ATP-mediated homo-oligomerization, translocation onto dsRNA, ubiquitination, and TRIM25- or Riplet-mediated ubiquitination, RLRs interact through their CARDs (orange) with the CARD of mitochondrion-associated MAVS (red). Signaling prosecution involves recruitment of TRAF3, NEMO and STING adaptors and the assembly of TBK1-IKK-ε complex, which phosphorylates IRFs. Activated IRF dimers translocate to the nucleus and, together with other transcription factors, induce the expression of IFN-α/β. Type I IFNs are secreted and bind to their cognate receptor, activating STAT transcription factors for the induction of several ISG products with antiviral activity and the overexpression of RLRs pathway components.

Essential for the prosecution of immune signaling, the redistribution of RIG-I from the cytosol to mitochondrial membranes is sustained by the formation of a translocon that involves the mitochondrion-targeting chaperone 14-3-3 ε and the tripartite motif 25 alpha (TRIM25α) E3 ligase ([@b0735]). Furthermore, in addition to RIG-I activation via unanchored polyubiquitin chains, Lys-63-linked polyubiquitination of RIG-I CARDs by TRIM25α was found to be important for the interaction with MAVS ([@b0425]). In turn, such activity of TRIM25α requires another E3 ligase, namely RING finger protein leading to RIG-I activation (Riplet) ([@b0955], [@b0950]), whose polyubiquitination of RIG-I CTD facilitates the release of CARDs and their association with TRIM25α ([@b0945]). At this point, the described mechanism, even though proposed as a general model for dsRNA recognition by RLRs, is mostly based on the characterization of RIG-I. However, the activation and signaling of MDA5 shows some differences. For instance, CARDs are not sequestered in the MDA5 resting form, and its activation -- for which both ATPase activity and Lys-63-linked ubiquitination are also important -- results in the cooperative assembly of MDA-5 protomers onto dsRNA helical filaments ([@b0090], [@b0585], [@b0980], [@b1335]). Next, prosecution of the pathway involves MAVS prion-like polymerization ([@b0545]) and the recruitment of two adaptors, tumor necrosis factor (TNF) receptor-associated factor 3 (TRAF3) and the nuclear factor-kB (NF-kB) essential modifier (NEMO), which connect and regulate signaling between the upstream sensory domain of MAVS and the downstream complex formed by TRAF family member-associated NF-kB activator (TANK)-binding kinase 1 (TBK-1) and inducible IkB kinase epsilon (IKK-ε) ([@b0935], [@b1400], [@b0085], [@b1270]). The two kinases TBK-1 and IKK-ε carry out the phosphorylation of latent IFN regulatory factors 3 and 7 (IRF-3/7), leading to their dimerization and nuclear translocation ([@b0380]).

It is worth noting that the recruitment of RIG-I to MAVS ([@b0735]) and the interaction of TBK1-IKK-ε complex with MAVS are two critical events for IRF phosphorylation. In particular, in the latter was found involved a newly-identified adaptor that acts as an RLR signaling enhancer, independently discovered by three research groups and variously termed stimulator of interferon genes (STING), mediator of IRF-3 activation (MITA) and endoplasmic reticulum IFN stimulator (ERIS), respectively ([@b0565], [@b1175], [@b1405]). Once in the nucleus, IRF-3 and 7 homo- or hetero-dimers associate into an enhanceosome with other transcription factors, such as cAMP response element-binding (CREB) binding protein/p300, NF-kB, activating transcription factor 2 (ATF-2) and c-Jun to drive the transcription of IFN-α/β genes ([@b0960]). In turn, secreted type I IFNs act towards the same cell, or the neighboring ones, by binding to their ubiquitous cognate receptors and activating a signaling cascade that ultimately leads to the expression of hundreds of IFN-stimulated genes (ISGs) with antiviral properties ([@b1100]). Some ISGs encode for effectors that are able to directly interfere with the viral replication cycle, such as the interferon-induced transmembrane (IFITM), ribonuclease L (RNase L), 2′, 5′-oligoadenylate synthetase (OAS), dsRNA-dependent protein kinase R (PKR), Viperin, myxovirus resistance 1 (Mx1) and interferon stimulated gene 15 (ISG15) proteins ([@b0745]). In addition, since among the ISGs products are also the PRRs, their adaptor molecules and transcription factors such as the IRFs, the expression of these proteins determines an amplification loop that increases both IFN-α/β and ISGs production, thereby establishing an overall antiviral state to limit virus spread and eventually clear the infection ([@b1100]).

4. RLRs: differential recognition of dsRNA agonists {#s0020}
===================================================

RIG-I and MDA5 helicases have been shown to preferentially sense different types of dsRNA PAMPs, based on their length, bluntness and end overhangs. RIG-I optimal ligands are short 5′-ppp-containing dsRNA molecules less than 20 bp in length ([@b0780], [@b0580], [@b1290]) and, while it can also bind 5′-hydroxyl (OH) blunt-ended dsRNA ([@b0775], [@b0800], [@b0665]), the presence of the 5′-ppp group is essential for its proper activation ([@b0540], [@b0995], [@b1070]). The 5′-ppp recognition is imparted by a set of key basic residues that form a positively-charged pocket within the RIG-I CTD, thus allowing efficient accommodation of the three phosphates ([@b0270], [@b0780], [@b1195]). However, even though RIG-I recognizes 5′-ppp dsRNA by end-capping it ([@b0775], [@b0800]), the 5′-ppp feature alone is not sufficient for efficient IFN induction, and at least small regions of dsRNA terminal base-pairing are required for proper interaction with the helicase ([@b0775]). In particular, double-strandness must encompass the 5′ nucleotide carrying the triphosphate and 5′ overhang at the 5′-ppp end abolishes RIG-I activity ([@b1115]). Instead, 3′ overhangs are tolerated, although decreasing RIG-I binding ([@b1115]) or supporting its ATPase activity without inducing IFN response ([@b1120]).

Moreover, despite the fact that 5′-monophosphate and 5′-OH groups at dsRNA ends are correlated with diminished RIG-I binding affinity and IFN induction ([@b1115], [@b1120]), such detrimental effect of 5′-ppp lack tends to vanish as the length of dsRNA substrate increases. In fact, provided the substrate is long enough, multiple internal initiation binding sites can compensate for the absence of the 5′-ppp at dsRNA ends ([@b0105]). In agreement with the cooperative oligomerization of RIG-I along dsRNA, whose efficiency is in turn correlated with the strength of IFN induction ([@b0975]), such flexible behavior allows RIG-I to integrate the two distinct signals of high-affinity motif and dsRNA length, thereby displaying the highest possible sensitivity in response to diverse PAMPs to be detected ([@b0105]).

Regarding MDA5, its optimal ligands were initially identified as blunt-ended dsRNA moieties more than 1 kbp in length ([@b0605]), while a subsequent study showed that this helicase is activated by an RNA web formed by branched dsRNA stretches ([@b0990]). Moreover, such high molecular weight moieties are bound by MDA5 regardless of the nature of the dsRNA 5′-ends, since the MDA5 CTD has a flat basic surface that lacks the RIG-I-like 5′-ppp-lodging pocket and does not cap dsRNA terminus ([@b0725], [@b1195]). Instead, MDA5 binds to the dsRNA backbone parallel to the helix axis and multimerizes into helical filaments along dsRNA ([@b0095], [@b1335]). Less is known about LGP2, the third member of the RLRs, which was shown to bind blunt-ended dsRNA in an ATP hydrolysis-dependent manner ([@b0145], [@b0890]) and regardless the presence of 5′-ppp ([@b0730], [@b1005]). Displaying a complex phenotype, LGP2 plays negative as well as positive roles in IFN induction. In fact, it negatively regulates RIG-I ([@b1095], [@b1355]) while it was shown to facilitate viral dsRNA recognition ([@b0145], [@b1105]) and to act as positive regulator of MDA5, with which it co-operates in response to polyI:C stimulation ([@b0220]).

The observed non-redundant abilities of RLRs to bind to diverse RNA ligands reflect their differential capacity to recognize various viral groups. In fact, while RIG-I preferentially recognizes 5′-ppp-containing self-paired panhandle RNAs, such those exhibited by several (−)-ssRNA viruses, (+)-ssRNA viruses that produce long blunt-ended RNA duplexes are mostly detected by MDA5. Notably, these patterns partially overlap, as some viruses are recognized by both RLRs ([@b0765], [@b0610]).

5. Hide, mask, hit: three viral strategies to block RLRs dsRNA detection {#s0025}
========================================================================

Obeying the ultimate goal of replicating in the host cell to generate new infectious virions, viral pathways include functionalities aimed to circumvent, downregulate or even totally suppress IFN-α/β induction, IFN-α/β signaling or ISG function ([@b1260]). Any of the several components involved in the different phases of the innate antiviral response can be targeted by viruses. However, the inhibition of IFN-α/β production achieved by blocking the RLR pathway in its upstream portion, at the level of dsRNA recognition, is a target shared by most viral antagonists, further evidencing the potency of such PAMP in triggering a robust innate immune response ([@b0125]). RNA viruses, of which several are pathogenic to humans, have developed a plethora of solutions to avoid dsRNA-mediated activation of RLRs. These can be ascribed to three strategies, hereby named as1.*Hide*, that indicates dsRNA sequestration to prevent its binding to RLRs, and is achieved either by viral proteins competing with RLRs for dsRNA binding or by shielding dsRNA through its compartmentalization within the cytoplasm ([Fig. 4](#f0020){ref-type="fig"} A);Fig. 4*Hide* and *Mask* strategies. Production of type I IFN-α/β is prevented by keeping RLRs from being triggered by short 5′-ppp dsRNA and long dsRNA molecules. (A) In the *Hide* strategy, nucleic acids are (i) bound by viral IFN-antagonists that compete with RLRs for the same binding sites on dsRNA backbone and/or terminal bases and phosphate groups; (ii) sequestered from RLRs recognition by compartmentalization into virally--assembled CMs and DMVs. (B) In the *Mask* strategy, viral IFN-antagonists remove PAMP signatures from dsRNA by (i) processing terminal 5′-ppp to monophosphate groups; (ii) digesting one nucleic acid strand through exoribonuclease activity.2.*Mask*, that relies on the ability of viral proteins to process double-helix and 5′-ppp termini, removing the PAMP signatures recognized by RLRs ([Fig. 4](#f0020){ref-type="fig"}B);3.*Hit*, that involves physical interaction between viral proteins and either RLRs or their downstream adaptors to suppress their functionalities ([Fig. 5](#f0025){ref-type="fig"} ).Fig. 5*Hit* strategy. In the *Hit* strategy, viral IFN antagonists suppress RLRs-mediated IFN-α/β induction by interacting with RLRs and their adaptor and/or effector molecules to inhibit their functionalities.

Due to the multifunctional nature of the viral proteins involved in these strategies, a certain degree of redundancy is present, with a given virus concomitantly adopting more than one strategy at a time through the action of one or more viral IFN-antagonists. Noteworthy, thanks to the recent availability of crystallographic structures of several viral proteins bound to their dsRNA ligands, some molecular details of the dsRNA *Hide* strategy are beginning to be unraveled. Conversely, the direct *Hit* towards RLRs, or their effectors, appears to be the most multifaceted strategy given the high number of cellular components involved so that, in most cases, the mechanism through which viral antagonists exert such inhibition still remain to be elucidated. According to these three strategies, we reviewed here solutions adopted by a number of RNA viruses that are highly lethal to humans and for which effective medical countermeasures are currently lacking ([Table 1](#t0005){ref-type="table"} ).Table 1Highly pathogenic RNA viruses which encode proteins that adopt the *Hide*, Mask and *Hit* strategies to block dsRNA recognition.FamilyVirusViral IFN-antagonist involved in targeting the RLRs pathway*HideMaskHitArenaviridae* (OW)LASFVNPNP, Z*Arenaviridae* (NW)JUNVNP, ZMACVNP, Z*Bunyaviridae*CCHFVL (?)vOTUHTNVL (?)GnRVFVNSs*Coronaviridae*SARS-CoVnsp4, Nnsp14ORF3b, ORF6, M, nsp3*Filoviridae*EBOVVP35VP35MARVVP35VP35*Flaviviridae*DENVNS4ANS3B2WNVNS4ANS3B2*Henipaviridae*HeVV, WNiVV, W*Orthomyxoviridae*IAVsNS1NS1, PB1, PB2, PA, PB1-F2[^1]

6. Arenaviruses {#s0030}
===============

Arenaviruses are mostly rodent-borne zoonotic pathogens with bi-segmented and ambisense ssRNA genomes that belong to the single genus *Arenavirus* of the family *Arenaviridae* and are the largest and worldwide distributed group of viruses causing hemorrhagic fever in humans ([@b0190]). On the basis of their antigenic properties, genetic relationships and geographical endemicity, members of this group are classified into Old World (OW) and New World (NW) arenaviruses. Among them, the OW Lassa fever virus (LASFV) and Lujo virus (LUJV), as well as the NW Chapare virus (CHPV), Guanarito virus (GTOV), Junin virus (JUNV), Machupo virus (MACV), Sabia virus (SABV) and Whitewater Arroyo virus (WWAV) have all been associated with fatal disease in humans ([@b0140], [@b0190], [@b0300]). 5′-ppp dsRNA moieties belonging to arenaviral genomes have been shown to activate the RLR pathway ([@b0480], [@b1415], [@b0550]). Moreover, suppression of the type I IFN response in cell culture assays by both OW and NW arenaviruses has been reported and related to the properties displayed by two of the four proteins encoded by the arenaviral genome: the nucleocapsid protein NP and (only for NW arenaviruses) the matrix protein Z ([@b0160], [@b0470], [@b0550], [@b0840], [@b0835], [@b0895]).

6.1. Mask {#s0035}
---------

The arenaviral NP is a multifunctional protein with essential roles in the replication and transcription of viral RNA ([@b0510], [@b1000]), in the encapsidation of viral genome into a ribonucleoprotein (RNP) complex ([@b0770]) and, together with the Z protein, in virion assembly ([@b0335]). Early studies identified NP as sufficient for the inhibition of IRF-3 phosphorylation and consequent suppression of IFN induction, thereby highlighting its innate immune antagonist nature ([@b0840], [@b0835]). Recently, structural and functional characterization of LASFV NP revealed that this property relies on the ability of the protein to process viral dsRNA with a 3′--5′ exoribonuclease activity ([Fig. 6](#f0045){ref-type="fig"} A). In fact, while the N-terminal NP folds into a domain important for mRNA capping during transcription, a large cavity within its C-terminal domain exhibits a dsRNA 3′--5′ exoribonuclease activity with a catalytic site comprising residues D389, E391, D466, D533 and H528, and structurally resembling the active sites of the DEDDH exonuclease superfamily ([@b1025]). Notably, these amino acids reside within the same NP region (residues 370--553) mapped for the anti-IFN activity of the OW lymphocytic choriomeningitis virus (LCMV), which contains critical residues along its DIEGR motif (residues 382--386) as well as at positions D459, H517 and D522 ([@b0590], [@b0830], [@b1025]).Fig. 6Structures of viral proteins dispaying the *Mask* and the *Hit* strategies. (A) LASFV NP *masks* dsRNA: LASFV may evade host cell dsRNA-induced innate immune antiviral response through the 3′--5′ exoribonuclease activity of its NP protein (highlighted in deep olive, PyMOL colors), which eliminates 5′-ppp and double-strandness PAMP signatures from viral dsRNA. Crystallographic structure by [@b0590] (PDB: 4G9Z); (B) CCHFV vOTU *hits* human Ubiquitin: CCHFV may downregulate RLRs pathway-mediated type I IFN production through the activity of its vOTU protease (highlighted in deep salmon, PyMOL colors), which removes ubiquitin (highlighted in gray, PyMOL colors) from RLRs, their adaptor and/or effector molecules, impairing their proper signaling. Crystallographic structure by [@b0150] (PDB: 3PRP); (C) Paramyxovirus V *hits* MDA5: HeV and NiV inhibit RLRs pathway-mediated IFN-α/β induction by preventing MDA5 activation and signaling through its sequestration by V protein. As shown in figure for the henipavirus closely-related PIV5, V protein zinc finger domain (highlighted in violet--purple, PyMOL colors) interacts with the Hel2 domain of MDA5 (highlighted in olive, PyMOL colors), thereby inhibiting its ATPase activity. Crystallographic structure by [@b0880] (PDB: 4I1S).

Alanine point mutation at each position of the LASFV NP 3′--5′ exoribonuclease active site, as well as at the two additional residues G392 and R492, resulted in markedly reduced exoribonuclease activity, without affecting the NP cap-binding function ([@b0515], [@b1025]). Notably, two of these residues were found to be critical for IFN suppression ([@b0830]), as the substitution into alanine of all of them caused complete inability of LASFV NP to inhibit SeV- or polyI:C-induced activation of the IFN-α/β promoter ([@b0515], [@b0590], [@b1025]).

Unlike other known DEDDH exonucleases, which split dsDNA to start digestion from an unpaired 3′-terminus, LASFV NP binds to dsRNA without unwinding its strands and, regardless of whether it bears overhanging or blunt-ended termini, with or without 5′-ppp, it readily digests the 3′-strand in the 5′-direction. ([@b0515], [@b0590], [@b1025]). It is therefore possible to envision the possibility that such processing removes from the viral dsRNA any PAMP hallmark that would be otherwise recognized by RLRs. The fact that critical residues for dsRNA exoribonuclease-mediated IFN inhibition are highly conserved among the NPs of all arenaviruses strongly suggests that this form of the *Mask* strategy is widely shared within the family ([@b1435], [@b0590], [@b1025]).

6.2. Hit {#s0040}
--------

As a remarkable example of IFN-antagonism redundancy, the same C-terminal NP region that is responsible for dsRNA masking was also found to exert a *Hit* strategy in both OW and NW arenaviruses. In fact, confocal microscopy and co-immunoprecipitation (co-IP) analyses have revealed that arenaviral NPs bind to the kinase domain of IKK-ε, blocking its autocatalytic activity and inhibiting the phosphorylation of IRF-3 substrate. IKK-ε sequestration by arenaviral NPs impedes the interaction between this kinase and its mitochondrial partner MAVS, thereby shutting down signaling along the RLR pathway ([@b1020]). Importantly, no interactions were observed between NP and other components of the pathway, such as TBK-1, MAVS, TRAF3 and even RIG-I or MDA5 ([@b1020]), although for the latter another study reported a co-IP with the NP of LCMV ([@b1415]). Notably, the NP-IKK-ε interaction is disrupted by mutating the same NP residues that are critical for its 3′--5′ exoribonuclease activity, suggesting the existence of an overlap in the domains responsible for the two IFN-antagonist functions ([@b1020]).

In the case of the NW arenaviruses, a *Hit* strategy against the RLRs pathway is also carried out, through the function exerted by the Z matrix protein, a small RING finger polypeptide that acts as a co-factor of the viral polymerase complex and also mediates both RNP incorporation into virions and their release from the plasma membrane ([@b0355]). Overexpression of the JUNV Z protein blocked IRF-3 and nuclear factor-kappa-B (NF-kB) phosphorylation and nuclear translocation, and decreased IFN-β mRNA levels in response to both SeV and 5′-ppp dsRNA stimulation ([@b0350], [@b0840], [@b0835]). Furthermore, confocal microscopy and co-IP revealed that the Z proteins of GTOV, JUNV, MACV and SABV, but not of LCMV and LASFV, are able to interact with RIG-I, preventing its recruitment to MAVS for downstream signaling ([@b0350]). The mechanism of such inhibiting interaction, as well as the molecular details in terms of involved domain/s and critical residues in the Z protein, remain to be elucidated.

7. Bunyaviruses {#s0045}
===============

Viruses of the *Bunyaviridae* family have a tripartite RNA genome with negative or ambisense coding strategy and are classified into the five genera *Orthobunyavirus*, *Hantavirus*, *Nairovirus*, *Phlebovirus* and *Tospovirus*. ([@b1265]). This group comprises zoonotic pathogens that are etiologic agents of severe disease in humans, characterized by high lethality, lack of preventive or therapeutic treatments and an emerging pattern at the human-wildlife interface ([@b1265]). Among these, the arthropod-borne Rift Valley fever virus (RVFV) from the genus *Phlebovirus* and the Crimean-Congo hemorrhagic fever virus (CCHFV) from the genus *Nairovirus* cause fulminating hemorrhagic fever ([@b0560], [@b0625]), while the rodent-borne Hantaan virus (HTNV), Sin Nombre virus (SNV) and Andes virus (ANDV) from the genus *Hantavirus* cause the typical hemorrhagic fevers with renal and cardio-pulmonary syndromes, respectively ([@b0190]). A new member of the genus *Phlebovirus*, severe fever with thrombocytopenia syndrome virus (SFTSV), was recently discovered and identified as the causative agent of a hemorrhagic fever with high fatality rates that has emerged in several provinces of China ([@b1375], [@b1390]).

As shown by *in vivo* studies, IFN-α/β is poorly induced in RVFV-infected animal models, and the late onset of the type I IFN response is correlated with increased viral pathogenicity ([@b0340]). IFN-α/β levels are kept very low in hantavirus-infected patients during the entire course of disease, and hantaviral species that are pathogenic to humans were found to be able to suppress IFN induction and signaling in cell culture assays much more efficiently than non-pathogenic viruses ([@b0340]). Moreover, a biphasic pattern was observed during hantavirus infection, in which IFN production is suppressed early, but a dramatic increase in ISGs expression occurs at later stages ([@b0845]). Likewise, type I IFN production and secretion is strongly delayed during CCHFV infection and virus replicating cells were found totally insensitive to IFN-α treatment ([@b0030], [@b1295]). A similar pattern of type I IFN response dysregulation was also observed for SFTSV, showing that human monocytes are susceptible to infection, mounting a restrained antiviral response with upregulation of some IFN-inducible proteins, but with very low levels of induced type I IFN ([@b1445]).

Taken together, these data indicate that the virulence and pathogenesis of bunyaviruses may be due, at least in part, to their ability to counteract cellular IFN responses ([@b1265]). Accordingly, *Mask* and *Hit* strategies here described are adopted by members of the genera *Hantavirus* and *Nairovirus* to escape RIG-I sensing. For RVFV, as well as for other viruses of the genera *Orthobunyavirus* and *Phlebovirus*, potent inhibition of the type I IFN-based antiviral response has been found as the result of the properties displayed by their NSs proteins ([@b0115]). Indeed, NSs proteins do not specifically target any of the above described components of the RLRs pathway; however, given that their action ultimately impedes the production of IFN-β ([@b0340]), the NSs strategy is *de facto* a *Hit* towards the pathway at its most basic level. By contrast, members of the genera *Hantavirus* and *Nairovirus* adopt *Mask* and *Hit* strategies aimed at directly escaping RIG-I sensing.

7.1. Mask {#s0050}
---------

Digestion with a specific 5′--3′ ssRNA exoribonuclease demonstrated that HTNV and CCHFV genomic RNAs bear a monophosphate group at the 5′ terminus, which may explain why such nucleic acids are not sensed by RIG-I ([@b0480]). HTNV 5′-ppp moieties are trimmed off during the synthesis of viral genome through a "prime and realign" process that cleaves the first-incorporated nucleotide leaving a 5′ monophosphorylated terminus ([@b0430]). Furthermore, in addition to being devoid of RIG-I-stimulating 5′-ppp, the HTNV genome has complementary 5′- and 3′-strands that form perfectly paired panhandle structures that are promptly encapsidated by viral nucleocapsid proteins ([@b0430]). For CCHFV, whose genomic RNA bears a terminal pyrimidine residue at the 5′-end, in place of the purine normally used by viral polymerases to initiate RNA synthesis, a similar "prime and realign" process likely occurs during replication ([@b0430]). However, the exact mechanism and viral proteins through which CCHFV removes protruding 5′-ppp from its genome ends is currently unknown ([@b0480]).

7.2. Hit {#s0055}
--------

Even though genomic HTNV and CCHFV RNAs do not significantly activate the RLRs pathway, dsRNA-like secondary structures able to stimulate RIG-I were observed in the mRNA transcripts of HTNV viral nucleoprotein ([@b0700]). Moreover, while HTNV replication was efficient in RIG-I knock-down A549 alveolar epithelial cells, it was strongly inhibited by transient overexpression of RIG-I in Huh7.5 cells that do not constitutively express this helicase ([@b0700]). It is not surprising that also pathogenic hantaviruses display a redundant *Hit* strategy to target components along the RLRs pathway. The ectopic expression of the hantaviral glycoprotein Gn, from the pathogenic New York-1 virus (NY-1V), was reported to inhibit IRF-3 phosphorylation as well as IRF-3-directed transcriptional response of IFN-β promoter ([@b0020]). Subsequent studies showed that such IFN antagonism is related to a 142-residue cytoplasmic Gn tail that is able to sequester the TRAF3 adaptor by binding to its N-terminal region, and that consequently inhibits the formation of a functional TBK1-TRAF3 complex ([@b0025]).

The presence of a viral homologue of the ovarian tumor protease domain (vOTU) ([Fig. 6](#f0045){ref-type="fig"}B) within the CCHFV RdRp polymerase L ([@b0405]) allows a cross-deubiquitinase proteolytic process for the removal of both poly-Ub and ISG15 from target proteins ([@b0150], [@b0575]). Notably, RIG-I ubiquitination by TRIM25α stabilizes its interaction with MAVS and enhances downstream signaling ([@b0425], [@b0420]). Similarly to ubiquitination, also K63-linked isopeptide-bond conjugation with ISG15 (ISGylation) of several target proteins is critical for IFN-α/β induction and antiviral activity in response to RNA virus infection, showing both positive and negative regulation of the RLRs pathway ([@b1395]). For example, IRF-3 ISGylation prevents its degradation and is required for efficient translocation and permanence into the nucleus ([@b0785]), while RIG-I ISGylation lowers its cellular levels to finely tune the antiviral response strength ([@b0635]). Therefore, vOTU deconjugation of Ub and ISG15 from RLRs pathway components seems to be a *Hit* strategy by which CCHFV evades IFN-based immune response, however further investigations are required to precisely define both mechanism of action and target proteins.

As the major virulence factor and IFN-antagonist of RVFV, NSs induces a complete shut-off of transcriptional activity in the infected cell, exerted through the sequestration of the p44 and XPD subunits of RNA polymerase II transcriptional factor TFIIH ([@b1440]) and by promoting the degradation of its p62 subunit ([@b0600]). Moreover, in addition to such generalized downregulation of host cell gene expression ([@b0100]), the RVFV NSs was shown to directly target the IFN-β production. In fact, by recruiting the repressor protein SAP30, NSs forms with it a multiprotein complex on the IFN-β promoter, thereby inhibiting its induction ([@b0690]). Recently, also the NSs of SFSTV, together with its N protein, were found to act as IFN-antagonists, as revealed by reporter gene assays that showed suppression of IFN-β and NF-kB promoters activity in response to polyI:C and IAV infection ([@b1445]). However, while the mechanism by which blockage of IFN production is achieved by both of these proteins is currently unknown, it is likely that inhibition would be exerted by SFSTV NSs through a yet-to-be-determined *Hit* strategy, as it was found able to co-precipitate with TBK-1 ([@b1445]).

8. Coronaviruses {#s0060}
================

Coronaviruses of the genus *Betacoronavirus* are (+)-ssRNA viruses in the family *Coronaviridae*, whose members cause important respiratory disease in humans ([@b0985]). In particular, the spillover from a zoonotic reservoir into the human population of Guandong province in southern China led in 2002 to the identification of a novel coronavirus (CoV) belonging to the genus *Betacoronavirus* ([@b0670]). Causing a "flu-like" disease characterized by severe acute respiratory syndrome (SARS) with high mortality rates, the SARS-CoV rapidly spread to many countries ([@b0555]). More recently, a novel CoV was identified in the Middle East as the causative agent of several acute respiratory syndrome with renal failure ([@b1380], [@b0630]). Tentatively named Middle East respiratory syndrome (MERS)-CoV, this pathogen has been responsible for more than 100 cases of lethal infection ([@b0285]).

Patients with SARS typically show aberrant type I IFN, ISGs and cytokine responses, suggesting that the virulence and pathogenicity of the SARS-CoV are related to profound dysregulation of the innate immune antiviral response ([@b1225]). Regarding the RLRs pathway, even though both RIG-I and MDA5 are overexpressed during SARS-CoV infection *in vitro* ([@b1365]), no IRF-3 phosphorylation or dimerization were observed and loss of IFN induction was reported in SARS-CoV-infected fibroblasts ([@b1215]). A similar pattern of poor IFN production and expression of pro-inflammatory cytokine was also observed in human bronchial epithelial cells infected with the MERS-CoV, and transcriptomic analysis of host gene expression showed upregulation of RIG-I, MDA5, IRFs and other ISGs ([@b0645], [@b0595]). In addition, comparative analysis of cell tropism and innate immune evasion showed that both viruses prevent IRF-3-mediated IFN-α/β induction, with MERS-CoV showing a higher sensitivity to IFN treatment ([@b0165], [@b0290], [@b1420]). Together, these data suggest that SARS-CoV and MERS-CoV employ strategies to counteract RLRs dsRNA recognition.

8.1. Hide {#s0065}
---------

The observation that in SARS-CoV-infected cells no type I IFN production was found, whereas treatment with polyI:C resulted in both IRF-3 activation and IFN-α/β induction ([@b1255], [@b1410]), strongly suggests that viral dsRNA is somehow buried and rendered inaccessible to cytoplasmic RLRs. In line with this, electron tomography studies have revealed that SARS-CoV infection alters the cytoplasmic membrane architecture by inducing the formation of a series of double-membrane vesicles (DMVs) which, interconnecting to each other without communicating with the cytosol, converge to the endoplasmic reticulum (ER) and the Golgi apparatus ([@b0650]). Membrane convolution into DMVs seems to be directed by the SARS-CoV nsp4 protein, as its mutation results in aberrant and open vesicles ([@b0255]). Furthermore, nsp3, nsp5 and nsp8 proteins, forming SARS-CoV replicase, as well as SARS-CoV genomic RNA all localize inside the DMVs, suggesting that viral RNA synthesis likely occurs at these intracellular sites ([@b1155], [@b1160]).

Notably, such extensive membrane re-arrangment, with DMV formation and co-localization with dsRNA was also observed in Vero cells infected with MERS-CoV, ([@b0290]). Hence, despite the substantial amount of dsRNA byproducts generated during SARS-CoV replication cycle ([@b1300]), it is likely that dsRNA shielding through its segregation into DMVs microenvironment is a *Hide* strategy through which CoVs effectively elude dsRNA detection ([@b0650]). However, such a passive mechanism is not exclusive, since the SARS-CoV N, a 46 kDa highly basic protein with a primary function of encapsidating the viral genome, has recently been found to target RLRs activation and signaling ([@b0790]). The SARS-CoV N protein inhibits IFN-α/β production induced by both SeV and polyI:C ([@b0660], [@b0790]) whereas, by contrast, it is not able to suppress type I IFN induction upon overexpression of components such as RIG-I-CARD, MAVS, TBK1 and IKK-ε, suggesting that the N protein blocks the initial step of dsRNA recognition by RLRs ([@b0790]). In addition, co-IP experiments have shown that the SARS-CoV N protein does not interact with either RIG-I or MDA5, thereby excluding the possibility that such a block is exerted by directly impairing RLRs function ([@b0790]). SARS-CoV N has been reported to be an RNA-binding protein ([@b0170], [@b1210]) through both its N-terminal and C-terminal domains ([@b0170], [@b0195]). Therefore, it is likely that SARS-CoV N binds dsRNA to prevent RIG-I and MDA5 activation and subsequent type I IFN induction ([@b0790]).

8.2. Mask {#s0070}
---------

A 3′--5′ exoribonuclease DEDDH domain was recently identified in the SARS-CoV nsp14 protein, demonstrating its ability to digest ssRNA as well as dsRNA with one 3′-mismatched nucleotide ([@b0120]). Primarily placed in the context of viral RNA synthesis, this nsp14 activity has been related to nucleotide misincorporation repair (i.e. proofreading) putatively exerted by the SARS-CoV polymerase complex. However, it is possible that this function is also related to the IFN-response evasion. In fact, as observed for the LASFV NP, such 3′--5′ exoribonuclease activity may serve for nsp14 degradation of dsRNA intermediates, thereby leading to inhibition of IFN induction ([@b0120]). However, albeit plausible, the formal involvement of nsp14 in a *Mask* strategy to prevent dsRNA detection requires further investigation.

8.3. Hit {#s0075}
--------

In addition to hiding and masking dsRNA, SARS-CoV IFN antagonism relies on directly targeting the RLR pathway. Several SARS-CoV encoded proteins have been found to display such properties, but the mechanism of action remains to be elucidated for most of them. The SARS-CoV ORF3b and ORF6 proteins are involved in suppressing IFN induction at the level of RLR signaling with their downstream adaptors. In fact, preferential localization and redistribution at the mitochondrial outer membrane of both ORF3b and ORF6 has been reported, seemingly associated with inhibition of RIG-I and MDA5 recruitment of MAVS ([@b0400], [@b0660]). Another SARS-CoV-encoded IFN antagonist protein is the structural glycosylated M protein, essential for the assembly of viral particles. SARS-CoV M exerts a double *Hit* strategy that results in the failure of IRF-3 phosphorylation and activation. First, SARS-CoV M interacts with RIG-I and MAVS, sequestering and re-localizing them into discrete membrane compartments associated with the Golgi apparatus ([@b1150]). Second, SARS-CoV M binds TRAF3 and, stably associating with it, abolishes the formation of a functional complex with the TBK1 and IKK-ε kinases ([@b1150]). Similarly, the papain-like protease (PLP) domain contained within the SARS-CoV nsp3 protein, an essential component of the viral replicase complex, interacts with the adaptor STING, impeding its dimerization and activation and disabling the STING essential function of MAVS recruiter to the TBK1-IKK-ε complex for IRF-3 phosphorylation ([@b0305], [@b1170]). Furthermore, a redundant inhibiting effect on RLR signaling is also due to the deubiquitinating activity of SARS-CoV PLP, that has been found to remove Ub from several RLR pathway components, such as RIG-I, STING, TBK1 and IRF-3 ([@b0250], [@b0410]).

9. Filoviruses {#s0080}
==============

Filoviruses are (−)-ssRNA viruses that belong to the family *Filoviridae*, which includes one species in the genus *Cuevavirus*, five species of Ebolaviruses (EBOVs) in the genus *Ebolavirus* and one species of Marburgvirus (MARV) in the genus *Marburgvirus,* and are among the most virulent known pathogens ([@b0675]). EBOVs and MARV are causative agents of fulminant hemorrhagic fever in humans and nonhuman primates, with up to 90% case fatality rates ([@b0505]). Even though rare and mostly confined to Sub-Saharan Africa and South-East Asia, filoviruses actually pose a worldwide concern. In fact, due to the risk of travel-imported cases, their demonstrated aerosol infectivity and transmissibility between pigs as well as their potential misuse as biological weapons in a bioterrorist attack, they are considered one of the highest priorities for global health security ([@b0130], [@b0810]).

The extreme lethality of EBOVs and MARV is the result of uncontrolled viral replication associated with a total impairment of the innate immune system, related, at least in part, to the properties displayed by three determinants of virulence and pathogenicity, namely the VP24, VP35 and VP40 proteins. However, only the multifunctional polymerase cofactor VP35 acts by suppressing IFN-α/β production, while the EBOV VP24 and MARV VP40 matrix proteins are involved in inhibiting the type I IFN signaling pathway ([@b0075], [@b1055]). Initially identified as the only filoviral protein able to complement the growth of a mutant IAV lacking its IFN-antagonist NS1 protein (see section 12) ([@b0065]), filoviral VP35 was found to suppress production of endogenous IFN-β as well as transcriptional activation of IFN-β, ISG54 and ISG56 promoters-driven reporter genes, induced by either mutant IAV infection, SeV infection or polyI:C dsRNA transfection ([@b0065], [@b0060], [@b0495]). These properties were correlated with the inhibition of IRF-3 phosphorylation, dimerization and nuclear translocation ([@b0155], [@b0495], [@b0500]), as well as inhibition of IFN-α/β promoter upon overexpression of either RIG-I, RIG-I CARD, MAVS, TBK1 and IKK-ε ([@b0155]). Together, these data indicate that the filoviral VP35 protein exerts its IFN-antagonism by targeting the RLR pathway.

9.1. Hide {#s0085}
---------

The innate immune escape capabilities exhibited by the filoviral VP35 all reside in its uniquely folded C-terminal RNA binding domain (RBD), also called the IFN-inhibitory domain (IID), comprising a central basic patch (CBP) that is highly conserved among filoviruses and shares high sequence identity with the IAV NS1 RBD ([@b0495], [@b0710], [@b0715]). Indeed, although the RBD/IID is sufficient by itself to display an anti-IFN phenotype, a full-length VP35 capable of homo-oligomerization is required for fully efficient IFN inhibition ([@b0710], [@b1075]). EBOV VP35 was found to be able to interact with dsRNA ([@b0155]), binding to both blunt-ended ([@b0360], [@b0640], [@b1425]) and 5′-ppp dsRNA molecules ([@b0720], [@b1430]) with very high affinity and in a sequence-independent manner. Notably, residues within the CBP critical for dsRNA binding such as R305, K309, R312 and K339 were found to be important for IFN inhibition, since their substitution with alanine decreased dsRNA binding to different extents ([@b0155], [@b1430]) and led to failure in suppressing both ISG56 and IFN-β promoter activity induced by various stimuli ([@b0155], [@b0495], [@b0500]). In particular, with respect to wt VP35, R312A VP35 showed the most dramatic defects, eliciting different ISGs expression profile in infected cells, and EBOV containing R312A VP35 mutation showed delayed viral growth and attenuation of infectivity in mice ([@b0485], [@b0490]). A similar defective phenotype was also generated by the double mutation K319A/R322A, causing total loss of VP35′s dsRNA binding activity, abolishing IFN inhibition and rendering the corresponding mutant EBOV avirulent in guinea pigs ([@b1015]). Notably, this double mutant was immunogenic and protected animals from subsequent challenge with wt EBOV ([@b1015]), strongly reinforcing the notion of a correlation between VP35 dsRNA binding, inhibition of IFN-α/β production and the pathogenicity of filoviruses.

The molecular details of the VP35 interaction with dsRNA have been solved by four crystallographic structures: two EBOV VP35 RBD/IID from the Zaire and Reston viruses bound to 8 and 18 bp blunt-ended dsRNA molecules, respectively ([@b0640], [@b0720]), and two crystallographic structures of the MARV VP35 RBD/IID bound to 12 and 18 bp blunt-ended dsRNA, respectively ([@b0040], [@b1050]). As observed in these crystals, EBOV VP35s form an asymmetric dimer at each of the dsRNA ends ([Fig. 7](#f0050){ref-type="fig"} A). One monomer, termed the backbone binding RBD/IID, binds to the sugar-phosphate backbone of both dsRNA strands, while the second monomer, referred to as end-capping, binds to dsRNA terminal bases and the proximal phosphate backbone. As a result of this bimodal strategy, VP35 RBD/IID dimers mimic the RLRs shape and hide their recognition site at dsRNA ends, possibly accommodating the 5′-ppp hindrance into a positively-charged pocket ([@b0720], [@b0640]). In contrast, MARV VP35 RBDs/IIDs have been reported to helically coat dsRNA along its entire phosphate backbone, with a footprint of four monomers every 4--5 bp ([Fig. 7](#f0050){ref-type="fig"}B) ([@b0040], [@b1050]). Notably, even though in this case no VP35 RBDs/IIDs capping of the nucleic acid ends was observed, isothermal titration calorimetry and dot blot assays revealed that a binding event with a VP35:dsRNA stoichiometry of 1:1 almost disappears in the presence of dsRNA overhangs, thereby suggesting that an end-capping-like binding dsRNA blunt-ends modality may also take place for MARV VP35 ([@b0040], [@b1050]).Fig. 7Structures of viral proteins displaying the *Hide* strategy. (A) EBOV VP35 *hides* dsRNA: EBOV suppresses IFN-α/β production through the properties of its VP35 protein, which sequesters dsRNA from RLRs detection. VP35 RBD shields RLRs recognition sites on a 8 bp dsRNA binding to its phosphate backbone (backbone-binding monomers, highlighted in gray, PyMOL colors) and to its terminal bases and phosphate groups (end-capping monomers, highlighted in light teal, PyMOL colors). Crystallographic structure by [@b0715], [@b0720] (PDB: 3L25); (B) MARV VP35 *hides* dsRNA: MARV VP35 RBD monomers fully coat a 12 bp dsRNA molecule along to its phosphate backbone. Crystallographic structure by [@b0040] (PDB: 4GHA); (C) IAV NS1 *hides* dsRNA: IAVs suppress type I IFN-based innate immune response through the properties of the multifunctional NS1 protein. The NS1 RBD dimer (highlighted in sky blue and light blue, PyMOL colors) coats dsRNA along to its phosphate backbone, thereby preventing its recognition by RLRs and PKR. Crystallographic structure by [@b0205] (PDB: 2ZKO).

More recently, a similar behavior was also described for the EBOV VP35 RBD/IID, and a model was proposed in which the end-capping monomer constitute the first binding event to which attachment of babckbone binding monomers follows ([@b0045]). As revealed by biochemical studies, EBOV VP35 RBDs/IIDs bind with similar affinities regardless of dsRNA length ([@b0720], [@b0640], [@b1050], [@b1430]), while MARV RBD/IID binding affinity decreases as dsRNA shortens ([@b0040], [@b1050]). In addition, dsRNA overhangs presence is barely tolerated by EBOV VP35, for which a 5′-ppp is otherwise important for binding to dsRNA with high affinity ([@b0640], [@b0720], [@b1430]), while they do not affect MARV VP35 binding function ([@b0040], [@b1050]). Such different abilities to recognize diverse dsRNA PAMPs reflect the diverse properties of the two filoviral VP35 in antagonizing RLRs. In fact, while both EBOV and MARV VP35 were able to inhibit the dsRNA-induced ATPase activity of MDA5, only EBOV VP35 exerted the same effect on RIG-I for all tested dsRNA ligands ([@b0720], [@b1050]).

Overall, the architecture of the VP35-dsRNA complex in the four crystallographic structures accounts for the importance of several residues in dsRNA binding. Side chains of residues R305/294, K309/298, R312/301, K339/K328 in the Zaire/Reston EBOV VP35 CBP ([@b0640], [@b0720]), as well as in the corresponding residues N261, Q263, R294, K298, S299, R301 and K328 in the MARV VP35 CBP, are all involved in direct interactions with the dsRNA phosphate backbone ([@b0040], [@b1050]). In addition, residues R312/301, K319/308, R322/311 and K339/328 in the Zaire/Reston EBOV VP35 CBP are also involved in protein--protein interactions at the RBD/IID dimer interface, while residues I340/329 and F239/228, in the end-capping monomer, interact with the adjacent K339/328, Q274/263 and I278/267 residues, which in turn bind dsRNA terminal bases ([@b0640], [@b0720]). Most importantly, the proposed model for filoviral VP35 homo-oligomers shielding dsRNA PAMP signatures has been validated by mutagenesis studies, since alanine substitutions of the same residues resulted in a decrease or loss of dsRNA binding function, as well as in diminished or abolished inhibition of SeV-induced IFN-β promoter activation and IRF-3 phosphorylation ([@b0040], [@b0640], [@b0720], [@b1050]). Hence, given the high degree of conservation of these amino acid residues among all known EBOV and MARV species, it is plausible that dsRNA sequestration by VP35 represents a key strategy through which these pathogens circumvent host innate immunity.

9.2. Hit {#s0090}
--------

In line with the other viral IFN-antagonist redundancy observed to concomitantly target multiple levels of the RLRs pathway, filoviral VP35 also employs several *Hit* strategies to suppress IFN-α/β induction. In fact, both EBOV and MARV VP35 were shown to block IRF-3 phosphorylation and nuclear translocation induced by TBK1 and IKK-ε overexpression, but not to inhibit IFN-β promoter activation induced by a constitutively active form of IRF-3 ([@b1010], [@b1050]). Consistent with a target upstream in the RLRs pathway, co-IP studies showed that EBOV VP35 interacts with the N-terminal domain of TBK1 and IKK-ε, it decreases their catalytic activity and is phosphorylated by these kinases ([@b1010]). In addition, overexpression of VP35 resulted in disruption of IKK-ε interactions with IRF-3, IRF-7 and MAVS ([@b1010]). Therefore, filoviral VP35 targets the RLRs pathway also in a dsRNA binding-independent way by acting as alternative substrate for the TBK1-IKK-ε complex in place of IRF-3 and 7. Furthermore, these two IRFs are also directly targeted by VP35 that prevents their migration to the nucleus ([@b0180]). In fact, EBOV VP35 was found to physically interact with both IRF-3 and 7 and to promote their Ub-like modification by the two members of the small Ub-like modifier cascade PIAS1 and Ubc9, thereby inhibiting the IRFs transcriptional function and subsequently suppressing the activation of IFN-β promoter ([@b0180]).

Finally, a novel mechanism through which VP35 suppresses the RLRs pathway was recently described, in which the EBOV IFN-antagonist interacts with cellular PKR activator (PACT), a dsRNA-binding protein involved in the activation of RIG-I and stimulation of its ATPase activity ([@b1450]; [@b0805]). The formation of a complex between VP35 and PACT abolishes critical interaction of the latter with the CTD of RIG-I, thereby preventing dsRNA-induced immune signaling ([@b0805]).

10. Flaviviruses {#s0095}
================

The genus *Flavivirus* of the family *Flaviviridae* includes two mosquito-borne (+)-ssRNA viruses, dengue virus (DENV) and West Nile virus (WNV), which are emerging as global life-threatening pathogens. WNV infects millions of people, with thousands of deaths annually, while DENV has spread worldwide, with a recent increase in morbidity and outbreak frequency ([@b0460], [@b0535]). DENV and WNV human infections are often asymptomatic or characterized by mild and self-limiting fever. In some cases, however, the infection develops into severe and fatal illness, characterized by hemorrhagic fever and shock syndrome for DENV, and by neurological diseases such as meningitis, encephalitis or acute flaccid paralysis in the case of WNV ([@b0460], [@b0535]).

The disease severity caused by these pathogenic flaviviruses has been correlated with their ability to counteract the IFN-α/β response ([@b0620]), and both DENV and WNV have been found to encode several IFN-antagonists acting on different targets ([@b0885]). However, most studies have focused on characterizing DENV and WNV suppression of the TLRs-mediated IFN induction, the IFN signaling pathway and the ISGs-mediated antiviral response, whereas less is known about viral proteins and mechanisms that interfere with the RLR pathway ([@b0875], [@b1185]). Notably, RIG-I, MDA5 and LGP2 are strongly up-regulated in several DENV- and WNV-infected cell lines ([@b0275], [@b0390], [@b1180], [@b1035]), while viral replication is enhanced in the absence of RLR expression ([@b0905], [@b1190]). Inhibition of IRF-3 phosphorylation has been reported during productive infection by both DENV and WNV, indicating that subversion of the RLR pathway is important for their replication ([@b0185], [@b0385], [@b0620]).

10.1. Hide {#s0100}
----------

DENV is able to efficiently downregulate RLR signaling ([@b0765]), even though its genomic RNA can be recognized by both RIG-I and MDA5 ([@b1085]). Similarly, WNV is able to elude RIG-I recognition early post-infection ([@b0395]), although its RNA subgenomic fragments fold into secondary structures that have recently been shown to potently activate RIG-I ([@b1145]). Together, these data make it plausible that flavivirus counteraction of the type I IFN-response may include mechanisms that avoid dsRNA detection. Supporting this hypothesis, two studies based on 3D electron tomography have shown that DENV and WNV modify ER and Golgi apparatus morphology, inducing the formation of convoluted membranes (CMs) in the cytoplasm. Tightly associated with the viral NS4A protein, CMs invaginations wrap around other NS proteins that form the viral replication machinery which, as revealed by immuno-labeling, co-localizes into the CMs vesicles packed with dsRNA ([@b0455], [@b1310]). By providing a hidden compartment where RNA synthesis and virus budding take place, such membrane modifications represent a passive strategy by which DENV and WNV hide dsRNA from RLRs.

10.2. Hit {#s0105}
---------

The RLRs pathway is also actively targeted by these two flaviviruses. In DENV infection, inhibition of SeV- or polyI:C-mediated transcriptional activity of the IFN-β promoter was found to be dose-dependently related to the catalytic activity of the NS2B3 protease ([@b1090]). As recently demonstrated, this correlation is due to the cleavage of the STING protein ([@b0005], [@b1370]) by a proteolytic core, within the last 40 amino acids of NS2 and the first 180 residues of NS3, which targets the consensus sequence LRRQ^96^G of STING, it eliminates its ability to interact with TBK1 and activates this kinase for IRF-3 phosphorylation ([@b0005], [@b1370]). In WNV infection, a possible *Hit* strategy to block RLRs signaling has been identified based on the viral protein NS2. By using a WNV subgenomic replicon, severe inhibition of IFN-β promoter-driven transcription was observed, and this phenotype was abolished by the occurrence of an adaptive alanine-to-proline substitution at position 30 of the NS2 protein ([@b0750]). With respect to wt NS2 WNV, A30P NS2 mutant WNV led to faster production of higher IFN-α/β levels in infected cells and determined an attenuation of viral growth and neuro-invasiveness in mouse models ([@b0755]). Furthermore, immunization of mice with this mutant WNV conferred protection against subsequent challenge with a lethal dose of a highly virulent WNV strain ([@b0755]). These data reflect the importance of WNV NS2 as a determinant of virulence and pathogenesis, even though the exact mechanism by which this protein modulates IFN-α/β expression remains to be determined.

11. Henipaviruses {#s0110}
=================

Within the viral family *Paramyxoviridae*, (+)-ssRNA viruses Hendra virus (HeV) and Nipah virus (NiV) of the genus *Henipavirus* have recently emerged as zoonotic bat-borne pathogens characterized by extreme lethality for humans and a broad mammalian host range ([@b0325]). Endemic in Australia and South-East Asia, respectively, HeV and NiV typically affect livestock but also cause severe neurologic and respiratory disease in humans that often progresses to encephalitis and multiorgan failure ([@b0825]).

As for the viruses discussed above, fatal outcome following henipavirus infection might be correlated with the ability of these pathogens to potently subvert the host innate immune system ([@b0070]). In agreement with this concept, daily treatment with IFN-inducers prevented death in NiV-infected animals ([@b0440]). Henipaviruses counteract the type I IFN response by blocking the IFN-α/β production at multiple levels ([@b0070]). This is the effect of the properties displayed by the four proteins encoded by the henipaviral P gene, which include the homonymous phosphoprotein P, together with viral products V, W and C ([@b1135]). The first three proteins are expressed by the same open reading frame (ORF), share a common N-terminal region and have a unique C-terminus. In fact, while the viral polymerase cofactor P is produced by the exact transcription of the entire gene, both V and W proteins are generated by an editing process based on the insertion of non-templated G nucleotide residues into the viral mRNA. By contrast, the C protein is expressed by an alternative ORF within the P gene, and therefore has a completely different sequence ([@b0680], [@b0760]). All proteins encoded by the henipaviral P gene act as determinants of virulence, inhibiting the IFN-α/β production by targeting both the TLR and RLR pathways, as well as suppressing type I IFN signaling ([@b0070]). With regard to the counteraction of RLR pathway, the discussion is limited only to functions displayed by the V and W proteins.

11.1. Hit {#s0115}
---------

The HeV and NiV V and W proteins are able to inhibit the SeV- and dsRNA-induced transcriptional activation of the ISG54 promoter by IRF-3 ([@b0070], [@b1135]). The V protein was shown to bind MDA5 ([@b0035], [@b0230]) and LGP2 ([@b0965]) by targeting homologous regions in the two helicases that, encompass residues 676--816 of MDA5 and residues 327--465 of LGP2, corresponding to the boundaries of their Hel2 domain ([@b0235], [@b0965]). As a consequence of this interaction with V, MDA5 dsRNA binding and homo-oligomerization were abolished ([@b0235]) and ATP-hydrolysis activity of both helicases were disrupted ([@b0965]). Moreover, even though henipaviral V proteins do not directly bind RIG-I ([@b0235]), their interaction with LGP2 induced the formation of a stable LGP2-RIG-I complex, rendering the latter unable to recognize 5′-ppp dsRNA ligands ([@b0225]).

The V protein domain responsible for such IFN-inhibiting activity was mapped to a region comprising 49--68 amino acids at its C-terminus, with one histidine and seven cysteine residues that are highly conserved among all paramyxoviruses and fold into a zinc-finger domain to coordinate two zinc atoms ([@b1045]). As revealed by mutagenesis studies, four residues in the zinc-coordinating domain, namely C194, C206, C208 and C211, as well as the two nearby conserved R409 and I414, are essential for the V protein's ability to suppress MDA5 functionality ([@b1045]). Conversely, the single amino acids R806 of MDA5, R455 of LGP2 and L714 of RIG-I are sufficient for the interaction with the viral protein, as their point mutation renders these helicases unable to co-immunoprecipitate with overexpressed V in luciferase-based cell culture assays ([@b1080]). The MDA5 crystallographic structure in complex with the V protein of the henipavirus closely-related parainfluenza virus 5 (PIV5) was recently obtained ([Fig. 6](#f0045){ref-type="fig"}C) ([@b0880]). As revealed by this structure, the zinc-finger β-hairpin located at the C-terminal domain of V is folded in a way that mimics the two β-strands in the MDA5 Hel2 domain ([@b0880]). As a result, upon interaction with MDA5, V displaces the β-sheet motif of the Hel2 domain and accommodates its zinc-finger β-hairpin into the MDA5 fold, thereby causing the inhibition of MDA5 ATP-hydrolysis activity, dsRNA binding ability and oligomerization properties, which ultimately inhibits the MDA5-induced production of IFN-α/β ([@b0880], [@b1330]).

The henipaviral W protein also downregulates type I IFN production, but the molecular mechanisms by which it targets the RLR pathway are less clear. In fact, the W protein was shown to potently block transcription from promoters activated by IRF-3, such as the IFN-α/β and the ISG54 promoters ([@b1140]). Moreover, since transcription starting at these IRF-3-responsive promoters was inhibited by henipaviral W also with concomitant overexpression of both TBK1 and IKK-ε kinases, it is conceivable that the target hit by this viral protein is placed downstream along the RLRs pathway ([@b1140]). Notably, due to a frameshift-extended ORF, W is about 43 amino acids longer than V, it lacks the domain responsible for interaction with RLRs and has a unique C-terminal basic stretch that functions as a nuclear localization signals (NLS) ([@b0760]). Therefore, given that W is almost exclusively nuclear and that it does not block IRF-3 phosphorylation, it is likely that this protein directly hits the transcriptional factor once in the nucleus, possibly rendering IRF-3 dimers less stable in order to prevent IFN-α/β promoter activation ([@b0760], [@b1140]). This mechanism of action would explain the ability of henipavirus W to impair both RLRs and TLR3 pathways, consistent with the hypothesis that it acts at a point in the pathways where the two signaling cascades converge ([@b0760], [@b1140]).

12. Influenza A viruses {#s0120}
=======================

Influenzaviruses are segmented (−)-ssRNA-viruses that belong to the three genera *Influenzavirus* A, B and C within the family *Orthomyxoviridae.* They are the most important respiratory pathogens affecting the human population. IAVs are maintained in several vertebrate host species and are subtyped according to the antigenic properties of their 16 different hemagglutinin and 9 different neuraminidase glycoproteins ([@b0850]). Subtypes that circulate in humans undergo an antigenic shift due to accumulation of mutations at these two proteins, which results in overcoming pre-existing immunity to cause seasonal flu epidemics worldwide. Occasionally, profound antigenic change may derive from interspecies transmission or gene re-assortment during concomitant infection of the same host by different IAV subtypes. If such antigenic drift occurs, viruses that are new to human population can emerge and generate devastating pandemics with millions of deaths ([@b0925], [@b0920]).

Human infections by highly pathogenic IAVs typically may result in acute respiratory distress syndrome with fatal pneumonia, due, at least in part, to the ability of IAVs to efficiently suppress the host innate immune response ([@b1060]). Regarding interference with the dsRNA-induced production of IFN-α/β, IAVs exert their antagonism through the properties of at least three proteins, namely NS1, PB2 and PB1-F2, which target the RLR pathway at several levels and with different mechanisms ([@b1235]).

12.1. Hide {#s0125}
----------

The notion that the multifunctional NS1 protein of IAVs is an IFN-antagonist derived from the finding that viruses deleted of its encoding gene (delNS1) showed attenuated growth and induced large amounts of IFN-α/β in IFN-competent cells, but replicated well in IFN-deficient cells ([@b0330], [@b0435]). Subsequent studies showed that this phenotype was the result of a counteraction towards the RLR pathway, as abrogated virus- and dsRNA-induced activation of IRF-3, NF-kB and the ATF-2/c-Jun enhanceosome ([@b0795], [@b1205], [@b1280]). Such inhibition was correlated with the ability of NS1 to bind dsRNA, since a binding-defective double mutant R38A/K41A NS1 led to virus attenuation *in vivo* and to IFN-α/β induction in cell cultures ([@b0315], [@b1205]). Notably, a third substitution at position 42 in the revertant NS1 mutant R38/K41A/S42G was reported to gain back IFN suppression capability but did not restore dsRNA binding, suggesting that, even though dsRNA binding is necessary and sufficient for efficient inhibition of IFN synthesis, it is not the sole function that mediate IFN antagonism by the IAV NS1 ([@b0315]). The impact of alternative mechanisms through which NS1 counteracts the host innate immune response (see below) was also highlighted by comparing NS1 proteins from different IAVs, which showed strain specificity in suppressing type I IFN and ISGs expression ([@b0655]). On the other hand, the importance of NS1 dsRNA-binding function for IFN antagonism was supported by the fact that the ability of RIG-I to detect IAV-derived RNAs was inhibited in the presence of NS1, but it was efficiently activated by the same PAMPs in cells infected with a virus lacking NS1 ([@b0080], [@b0540], [@b0995]).

NS1 binds to blunt-ended and 5′-ppp dsRNA as well as ssRNA panhandle structures through an N-terminal RBD that encompasses residues 1--73 ([@b0215], [@b0520], [@b1030]). Moreover, NS1 proteins deleted in their C-terminal effector domains were still active in blocking activation of IFN-β promoter ([@b0475], [@b0530]). Functional proteins were obtained even when the sole NS1 N-terminal dsRNA binding domain was fused to a heterologous C-terminal domain ([@b1285]), reinforcing the importance of dsRNA sequestration by preventing RLR recognition and subsequent IFN-α/β production.

Structural evidence indicates that NS1 exists as a homo-dimer and interacts with the phosphate backbone of dsRNA, so that the two RBD monomers lie on nucleic acid strands like parallel tracks on a slot ([@b0210], [@b0740], [@b1275]). Along these tracks, several conserved basic and hydrophobic residues such as T5, P31, D34, R35, R38, K41, G45, R46 and T49 have been identified as critical for NS1 dsRNA-binding ability ([@b1275], [@b1350]). In fact, as revealed by the crystal structures of the NS1 RBD in complex with a 21-bp dsRNA ([Fig. 7](#f0050){ref-type="fig"}C), these residues form a concave surface that recognizes the minor groove of the dsRNA A-form ([@b0205]). In particular, residues R38, S42 and T49 of each RBD, as well as arginines at positions 35 and 46 from different monomers, are involved in establishing key hydrogen bonds with the phosphate group of both dsRNA strands ([@b0205]). Furthermore, an even more evocative description of how IAVs prevent the detection of dsRNA by RLRs has come from the solved structure of a full-length NS1 of the highly pathogenic H5N1 IAV in complex with dsRNA ([@b0110]). As shown by a combined X-ray crystallography and cryo-EM approach, NS1 dimers multimerize through alternating interactions between the RBD and the C-terminal effector domain, forming a tubular structure with a central tunnel suitable to accommodate dsRNA ([@b0110]). Again, critical orientation is observed for key residues such as R38, which is projected to the tunnel center in order to establish direct bonds with dsRNA, while other residues like K41 contribute to enwrap the phosphate backbone all along the entire nucleic acid length ([@b0110]).

12.2. Hit {#s0130}
---------

NS1 also exerts its IFN-inhibiting properties against the RLR pathway through *Hit* strategies, since it was found to be able to block both RIG-I and MAVS functions by physically interacting with these components ([@b0475], [@b0860], [@b0940]). Noteworthy, the presence of 5′-ppp dsRNA enhanced co-precipitation with RIG-I, and such interaction was abolished in the dsRNA binding-defective R38A/K41A mutant, suggesting either the possibility of overlapping functions in the NS1 RBD or a role of dsRNA as intermediate in the formation of the NS1-RIG-I complex ([@b0995], [@b1205]).

RLR activation and signaling are also blocked by NS1 through the suppression of RIG-I K63-linked ubiquitination by TRIM25α ([@b0415]). Specifically, NS1 interacts with the coiled-coil domain of TRIM25α and disrupts its homo-oligomerization, which is in turn indispensable for poly-ubiquitination of RIG-I ([@b0415]). Moreover, the alanine substitution of E96 and E97 residues as well as the R38A/K41A mutation responsible for loss of dsRNA binding impaired NS1 interaction with TRIM25α and caused attenuation of viral growth *in vivo* and increased IFN-α/β production ([@b0415]). Also, the TRIM25α-orthologue Riplet was recently found to be a target, in human cells, of NS1 from human IAV strains. However, while the E96A/E97A mutant was in this case still capable of such interaction, the dsRNA binding-defective R38A/K41A NS1 could not exert it ([@b1040]). Finally, the NS1 proteins of most (but not all) IAVs are able to alter innate immune responses through a global restriction of host gene expression. To achieve this, NS1 binds the 30 kDa subunit of cleavage and polyadenylation-specificity factor (CPSF30) ([@b0910], [@b0930], [@b0280]), preventing polyadenylation of the 3′ ends of host pre-mRNA, and interacts with the poly-(A)-binding protein II (PABPII), resulting in inhibition of host pre-mRNA nuclear export ([@b0200]).

In addition to NS1, the other IAV proteins PB1, PB2, PA and PB1-F2 all display IFN-antagonism against the RLR pathway by targeting the mitochondrial adaptor MAVS through a *Hit* strategy. The three RNA polymerase subunits PB1, PB2 and PA were all found to inhibit dsRNA-induced and RIG-I- or MDA5-mediated activation of IFN-β promoter in a gene reporter assay, and such inhibition was related to their binding to MAVS ([@b0570]). In PB2, whose inhibitory effect and binding ability were stronger, amino acids 1--37 were found to be critical for the interaction with the N-terminal 150 residues of MAVS, while an asparagine at position 9 in PB2 sequence was found to be essential for its mitochondrial localization and inhibition of the RLR pathway signaling ([@b0465], [@b0970]). Regarding PB1-F2, this small protein encoded by a +1 ORF in the PB1 gene is found only in some IAVs and its presence is related to the high virulence in a strain-dependent manner ([@b1125], [@b1245]). PB1-F2 strongly suppresses RIG-I-mediated IFN-α/β induction, whereas infection with delPB1-F2 viruses results in increased IRF-3 activation and production of IFN-β mRNA ([@b0320]). Initially, such activity was found to be mediated by a region spanning residues 39--87 of the PB1-F2 C-terminus, where a highly conserved sequence served as a mitochondrial targeting signal (MTS) ([@b0450], [@b1250], [@b1345]). More recently, the presence of a serine in place of the asparagine at position 66 within the PB1-F2 MTS was found to be related to a severe pathogenicity and a strong reduction of ISGs expression, and to be responsible for the increased virulence of the avian H5N1 and the 1918 Spanish flu IAV strains ([@b0265], [@b0260]). In line with these data, the mechanism of action through which PB1-F2 shuts down type I IFN production has been elucidated by recent work demonstrating that PB1-F2 physically interacts with MAVS, and that the N66S mutation enhances this interaction ([@b1240]). PB1-F2 also targets the transmembrane region of MAVS, dissipating the mitochondrion membrane potential that is an important factor for the recruitment of downstream components and the prosecution of the RLRs signaling cascade ([@b1240]).

13. Concluding remarks and future challenges {#s0135}
============================================

Based on the production of type I IFN in response to viral infections, the intrinsic innate immune system is an integral part of the broader immune system of vertebrates, and both cell-mediated and humoral adaptive immune responses depend on its proper function. Prompt detection of the pathogen, which relies on the recognition of its molecular components, is a prerequisite for IFN production, and dsRNA is the hallmark of virus presence, above all PAMPs. In the cytoplasm, dsRNA recognition is assigned to the RLRs. Viruses, in turn, circumvent this detection through an array of mechanisms aimed to suppress the RLR pathway. Within this array, we have described three main viral strategies, which are respectively directed to hide dsRNA from RLRs, to mask its presence by modifying its molecular features and to directly hit RLRs and their adaptors and/or effectors to impair their functions. These strategies, even though put in place through different molecular mechanisms, represent one aspect of the overall process by which adaptation between any given virus and the organism it infects was established. However, while the result of this coevolution and interplay is a fine modulation of the maintenance host's innate immune system, to circumvent its effects, spillover of the virus to a new host species may lead to new fortuitous interactions with diverse intracellular machineries, often causing the dramatic effects of an overwhelming infection.

In line with this consideration, for all of the highly pathogenic RNA viruses here examined, the proteins involved in countering host dsRNA-induced IFN production were also found to act as determinants of virulence and pathogenesis. Moreover, in several cases, point mutations that impair their anti-IFN functions cause a loss of virus lethality. Together with the fact that the functional domains responsible for IFN antagonism are highly conserved within each viral group, this indicates that these viral proteins are attractive and promising targets for antiviral development. Additionally, given the importance of the RLRs pathway, it is also possible to envision the strategy of developing compounds that, mimicking the triggering power of dsRNA, may be able to boost the intrinsic innate immune system to obtain a preventive/aiding activation against viral infections. To this aim, tremendous advances in our knowledge are provided by the crystallographic structures of several viral IFN-antagonists as well as by the elucidation of their mechanism of action.

Finally, it is worth noting that many questions still remain unanswered regarding the different effects of the described viral proteins on the RLR pathway in human cells, on the one side, and in the natural reservoirs of these lethal pathogens, on the other, since these animals are infected asymptomatically and do not develop disease. In fact, assuming that viral proteins have evolved to finely tune the host innate antiviral response, rather than to completely suppress it, the understanding of the subtle differences between the innate immune antiviral response in humans and in these viruses' animal reservoirs will also be of paramount importance for the development of effective viral therapeutics, making it possible to shift the balance from a fatal outcome to the clearance of infection.

[^1]: CCHFV, Crimean-Congo hemorrhagic fever virus; DENV, dengue virus; EBOV, Ebola virus; HTNV, Hantaan virus; HeV, Hendra virus; IAVs, influenza A viruses; JUNV, Junin virus; LASFV, Lassa fever virus; MACV, Machupo virus; MARV, Marburg virus; NiV, Nipah virus; RVFV, Rift Valley fever virus; SARS-CoV, severe acute respiratory syndrome coronavirus; WNV, West Nile virus.
